As on Wednesday, Atossa Therapeutics Inc (NASDAQ: ATOS) got off with the flyer as it spiked 1.67% to $1.83, before settling in for the price of $1.80 at the close. Taking a more long-term approach, ATOS posted a 52-week range of $0.59-$1.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was 54.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -14.29%. This publicly-traded company’s shares outstanding now amounts to $126.62 million, simultaneously with a float of $125.28 million. The organization now has a market capitalization sitting at $229.30 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0871, while the 200-day Moving Average is $0.9173.
Atossa Therapeutics Inc (ATOS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Atossa Therapeutics Inc’s current insider ownership accounts for 0.02%, in contrast to 19.14% institutional ownership. According to the most recent insider trade that took place on Nov 15 ’23, this organization’s Former EVP, CFO, & Director sold 50,000 shares at the rate of 0.65, making the entire transaction reach 32,500 in total value, affecting insider ownership by 55.
Atossa Therapeutics Inc (ATOS) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.05 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.07) by $0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
Atossa Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -14.29% and is forecasted to reach -0.26 in the upcoming year.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Let’s observe the current performance indicators for Atossa Therapeutics Inc (ATOS). It’s Quick Ratio in the last reported quarter now stands at 28.35. The Stock has managed to achieve an average true range (ATR) of 0.14.
In the same vein, ATOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.24, a figure that is expected to reach -0.06 in the next quarter, and analysts are predicting that it will be -0.26 at the market close of one year from today.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Through scrutinizing the latest numbers posted by the [Atossa Therapeutics Inc, ATOS], it can be observed that its last 5-days Average volume of 2.8 million was better the volume of 0.96 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 89.80% While, its Average True Range was 0.1618.
Raw Stochastic average of Atossa Therapeutics Inc (ATOS) in the period of the previous 100 days is set at 91.67%, which indicates a major rise in contrast to 87.21% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 103.79% that was higher than 71.95% volatility it exhibited in the past 100-days period.
